Nuvation Bio Inc - Ordinary Shares - Class A
NUVB
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.74B
Close$
$1.22
74% downside
Current Fair Value
74% downsideOvervalued by 74% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.74 Billion |
|---|---|
| Enterprise Value | $1.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.6 |
| Beta | 1.62 |
| Outstanding Shares | 348,770,000 |
Return
| Return on Equity | -59.02% |
|---|---|
| Return on Assets | -20.12% |
| Return on Invested Capital | -21.06% |
Valuation & Multiples
| P/E Ratio | -11.51 |
|---|---|
| PEG | -177.15 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.23 |
| Enterprise Value to EBIT | -12.55 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 1.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$27.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$34.81 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 4.57% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 67.77% |
|---|---|
| Total Invested | $326,934▼ 99.98% |
| Investors Holding | 7▼ 244.00% |
ESG Score
No data
About Nuvation Bio Inc
36 employeesNuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...